Drugs / AMA0076
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03586908 | Feb 2018 | — | pH Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02003547 | Sep → Dec 2013 | glaucoma, ocular hypertension | Amakem, NV | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03106532 | Mar 2017 → May 2018 | low tension glaucoma | pH Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02136940 | Apr → Nov 2014 | glaucoma, ocular hypertension | Amakem, NV | Completed | No outcome recorded |
| Phase 2 | NCT01693315 | Sep 2012 → Jul 2013 | glaucoma, ocular hypertension | Amakem, NV | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04863365 | Nov 2021 → Nov 2023 | ocular hypertension, open-angle glaucoma | pH Pharma | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMA0076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01693315 ↗ |
| Known as | PHP-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03586908 ↗ |
| Known as | Sovesudil | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545073 ↗ |
| Action | Inhibit | “As a selective ROCK inhibitor” NCT04863365 ↗ |
| Route | Topical | “Topical Ocular Formulation” NCT01693315 ↗ |